| Budget Amount *help |
¥43,160,000 (Direct Cost: ¥33,200,000、Indirect Cost: ¥9,960,000)
Fiscal Year 2020: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2019: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2018: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2017: ¥8,450,000 (Direct Cost: ¥6,500,000、Indirect Cost: ¥1,950,000)
Fiscal Year 2016: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
|
|---|
| Outline of Final Research Achievements |
Mouse monoclonal antibodies with cross-neutralizing activity against multiple ebolavirus species were generated. Detailed analyses of the epitopes recognized by the antibodies suggested that that some of the antibodies bind to the side region of the viral surface glycoprotein (GP) molecule and inhibit the membrane fusion between the cellular membrane and the virus envelope. Electron microscopic structural analysis of the complex of the GP molecule and Mab 6D6, one of the cross-reactive antibodies, revealed that this antibody recognizes the fusion loop region of GP. In addition, a novel compound having the ability to reduce the infectivity of all known ebolaviruses were obtained from an existing compound library. It was suggested that this compound binds to the side surface region of the GP molecule and inhibits the membrane fusion.
|
